| European Case Law Identifier: | ECLI:EP:BA:2016:T159212.20161025 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 25 October 2016 | ||||||||
| Case number: | T 1592/12 | ||||||||
| Application number: | 00959423.5 | ||||||||
| IPC class: | A61K 39/395 C07K 16/32 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | D | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Dosages for treatment with anti-ErbB2 antibodies | ||||||||
| Applicant name: | Genentech, Inc. | ||||||||
| Opponent name: | BioGeneriX AG Stada R & D GmbH Teva Pharmaceutical Industries Ltd. Celltrion, Inc. Sandoz AG Synthon B.V. |
||||||||
| Board: | 3.3.04 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Sufficiency of disclosure - main (sole) request (no) | ||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t121592eu1.html
Date retrieved: 17 May 2021